methyl 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-benzyloxy-benzoylamino}-3-pyridinecarboxylate | 851884-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-benzyloxy-benzoylamino}-3-pyridinecarboxylate
• 英文别名: methyl 6-[[3-phenylmethoxy-5-[(2S)-1-phenylpropan-2-yl]oxybenzoyl]amino]pyridine-3-carboxylate
• CAS: 851884-90-7
• 化学式: C₃₀H₂₈N₂O₅
• 分子量: 496.563
• InChiKey: IUIPVZZFJZRKNP-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-benzyloxy-benzoylamino}-3-pyridinecarboxylate 在 palladium 10% on activated carbon 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 methyl 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-hydroxy-benzoylamino}-3-pyridinecarboxylate
  参考文献：
  名称：

  [EN] PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS
  [FR] DERIVES D'ACIDES CARBOXYLIQUE DE PYRIDINE EN TANT QUE MODULATEURS DE LA GLUCOKINASE

  摘要：

  式(I)的化合物：其中：A为苯基或5-或6-成员杂环芳基环，可选择地取代；R1和R2从氢和甲基中选取；条件是R1和R2中至少有一个为甲基；或其盐、前药或溶剂化合物。描述了它们作为GLK激活剂的用途，含有它们的药物组合物以及它们的制备方法。

  公开号：

  WO2005044801A1
• 作为产物：
  描述：

  6-氨基烟酸甲酯 、 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 生成 methyl 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-benzyloxy-benzoylamino}-3-pyridinecarboxylate
  参考文献：
  名称：

  [EN] PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS
  [FR] DERIVES D'ACIDES CARBOXYLIQUE DE PYRIDINE EN TANT QUE MODULATEURS DE LA GLUCOKINASE

  摘要：

  式(I)的化合物：其中：A为苯基或5-或6-成员杂环芳基环，可选择地取代；R1和R2从氢和甲基中选取；条件是R1和R2中至少有一个为甲基；或其盐、前药或溶剂化合物。描述了它们作为GLK激活剂的用途，含有它们的药物组合物以及它们的制备方法。

  公开号：

  WO2005044801A1

文献信息

• PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS
  申请人：Caulkett William Rodney Peter

  公开号：US20070078168A1

  公开（公告）日：2007-04-05

  A compound of Formula (I): wherein: A is phenyl or a 5- or 6-membered heteroaryl ring, optionally substituted; R 1 and R 2 are selected from hydrogen and methyl; with the proviso that at least one of R 1 and R 2 is methyl; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  公式（I）的化合物：其中：A为苯基或5或6成员的杂环芳基环，可选择取代；R1和R2为氢或甲基；但至少有一个R1和R2为甲基；或其盐、前药或溶剂化物。描述了它们作为GLK激活剂的用途，包含它们的制药组合物以及它们的制备方法。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。
• AROMATIC COMPOUND
  申请人：FUKUSHIMA Tae

  公开号：US20120238750A1

  公开（公告）日：2012-09-20

  The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group —Z—R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的化合物由以下通式（1）表示：[其中X1表示氮原子或基团—CH═; R1表示基团—Z—R6，其中Z表示基团—CO—、基团—CH（OH）—或类似物，而R6表示具有1至4个氮原子、氧原子或硫原子的5至15环的单环、双环或三环、饱和或不饱和的杂环基团; R2表示氢原子、卤素原子或较低的烷基链; Y表示基团—O—、基团—CO—、基团—CH（OH）—、较低的烷基链或类似物; A表示基团或类似物，其中R3表示氢原子、较低的烷氧基或类似物，p表示1或2，而R4表示咪唑基较低的烷基链或类似物。
• US8188277B2
  申请人：——

  公开号：US8188277B2

  公开（公告）日：2012-05-29
• [EN] PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS<br/>[FR] DERIVES D'ACIDES CARBOXYLIQUE DE PYRIDINE EN TANT QUE MODULATEURS DE LA GLUCOKINASE
  申请人：ASTRAZENECA AB

  公开号：WO2005044801A1

  公开（公告）日：2005-05-19

  A compound of Formula (I): wherein: A is phenyl or a 5- or 6-membered heteroaryl ring, optionally substituted; R1 and R2 are selected from hydrogen and methyl; with the proviso that at least one of R1 and R2 is methyl; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  式(I)的化合物：其中：A为苯基或5-或6-成员杂环芳基环，可选择地取代；R1和R2从氢和甲基中选取；条件是R1和R2中至少有一个为甲基；或其盐、前药或溶剂化合物。描述了它们作为GLK激活剂的用途，含有它们的药物组合物以及它们的制备方法。